A Deeper Look into Novel Potassium Binders in the Management of Hyperkalemia with End Stage Renal Disease: Individualizing Treatment for Improved Clinical and Cost Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

Therapeutic Advances in the Management of Hyperkalemia with End Stage
Renal Disease: Improving Clinical and Cost Outcomes in an Evolving
Treatment Paradigm is a three-part webinar series.

This is Part 1 of the series focusing on the management of Hyperkalemia in
patients with End Stage Renal Disease.

This activity is an archive from the webinar held October 21, 2020

This activity is valid from November 1, 2020 to November 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca

Description:
Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.

Upon completion of this activity, participants will be able to:

  • Analyze the clinical and economic burden of hyperkalemia and the impact of suboptimal management on outcomes

  • Identify the risk factors and pathophysiologic mechanisms associated with the development of hyperkalemia in key patient populations

  • Evaluate recent potassium binders in terms of safety, efficacy, labeling, dosing and role in hyperkalemia with end stage renal disease management strategies

  • Identify patients with hyperkalemia with end stage renal disease who would potentially benefit from a novel potassium binder therapy

     

Faculty: Javed Butler, MD, MBA, MPH
Patrick A. Lehan Chair in Cardiovascular Research
Professor of Medicine and Physiology
University of Mississippi

Disclosure:

Dr. Butler serves as a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, V-Wave Limited, and Vifor. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue